Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: PG stock price vs ILMN: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ILMN's multiple
Needs ILMN P/E.
Implied fair value · at PG's multiple
Needs PG P/E.
Price unavailable
Metric by metric
Where each company leads, and how wide the gap is.
Growth edge
Reported gross margin
Operating income + D&A
Lower is better
Not comparable
Lower leverage
Statements
Annual statements in reported currencies, with calculations and source evidence.
Values retain reported currencies and share bases. Select a figure to inspect its period, calculation and filing inputs. Differences require compatible units and periods.
Explore enterprise value and market valuation multiples in the valuation sections.
Trendline
Ten period-end years of reported revenue, earnings, and margins. Periods and currencies are shown with the data.
Price framework
USD market cap plus reported borrowing debt, less cash and equivalents. This EV proxy excludes investments, preferred stock and noncontrolling-interest adjustments.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
The Procter & Gamble Company · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
ILLUMINA, INC. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Inspect reported liquidity and leverage alongside historical financial-health checks.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Cash excludes investments. EBITDA is an operating-income-plus-D&A proxy. Missing borrowing categories remain unavailable; select a value to inspect its inputs.
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
COLGATE PALMOLIVE CO
PG vs CL
KIMBERLY CLARK CORP
PG vs KMB
CHURCH & DWIGHT CO INC /DE/
PG vs CHD
CLOROX CO /DE/
PG vs CLX
Johnson & Johnson
PG vs JNJ
THERMO FISHER SCIENTIFIC INC.
PG vs TMO
AGILENT TECHNOLOGIES, INC.
PG vs A
DANAHER CORP /DE/
PG vs DHR
BIO-RAD LABORATORIES, INC.
PG vs BIO
PACIFIC BIOSCIENCES OF CALIFORNIA, INC.
PG vs PACB
Natera, Inc.
PG vs NTRA
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
This explanation uses an earlier data snapshot or evidence version. Review its generation date and the current figures, or refresh after signing in.
If you believe PG’s earnings multiple should remain supported by its scale, operating margin, and low distress risk, then hold or accumulate PG because the implied P/E value is far above the current price despite the DCF range arguing for caution.
On a P/E basis, PG trades at 22.2x versus ILMN at 37.6x, which makes PG look cheaper on earnings. However, ILMN trades at a lower P/S multiple than its earnings multiple would imply only because its revenue base is much smaller, while PG’s current price sits well below the implied P/E value of $244.99 but inside its historical band.
Supporting Metrics
